Phase II study of Proteasome inhibitor Bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma unspecified PTCLU and cutaneous T-cell lymphoma CTCL.

Trial Profile

Phase II study of Proteasome inhibitor Bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma unspecified PTCLU and cutaneous T-cell lymphoma CTCL.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 May 2011

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top